Faria, João http://orcid.org/0000-0002-2893-5030
Calcat-i-Cervera, Sandra http://orcid.org/0000-0002-2300-7104
Skovronova, Renata http://orcid.org/0000-0003-0217-5309
Broeksma, Bonnie C.
Berends, Alinda J.
Zaal, Esther A. http://orcid.org/0000-0001-9890-7345
Bussolati, Benedetta http://orcid.org/0000-0002-3663-5134
O’Brien, Timothy http://orcid.org/0000-0001-9028-5481
Mihăilă, Silvia M. http://orcid.org/0000-0001-8791-3918
Masereeuw, Rosalinde http://orcid.org/0000-0002-1560-1074
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (813839)
Article History
Received: 28 July 2023
Accepted: 6 November 2023
First Online: 10 December 2023
Declarations
:
: A-MSCs from lipoaspirates (healthy donors of both gender in a range of age 47–25 years) were processed in Heidelberg after obtaining informed consent (title of approved project: isolation and characterization of MSCs from human adipose tissue; institutional approval committee: Mannheim Ethics Commission II; approval number: 2006-192N-MA; date of approval: 18.04.2005, re-confirmed 26.02.2009 with subsequent approvals). BM-MSCs provided by Galway were isolated from bone marrow aspirates (healthy young male donors) purchased from Lonza (Basel, Switzerland) (title of approved project: Isolation of Human Marrow Stem Cells from Healthy Donors; Bone Marrow Research Study”, institutional approval committee: Galway University Hospital Clinical Research Ethics Committee; approval number: 02/08; date of approval: November 2008 with subsequent approvals for amendments). UC-MSCs with informed consent obtained in accordance with the Declaration of Helsinki were sourced from the NHS Blood and Transplant and transferred to the University of Liverpool (project title: the provision of mesenchymal stromal cells to the University of Liverpool for use in the RenalToolBox project; institutional approval unit: NHS Blood and Transplant, Cellular and Molecular Therapies; approval number: RTB21112019; date of approval: 21 November 2019).
: Not applicable.
: The authors declare no conflict of interest with the contents of this article. Rosalinde Masereeuw is co-inventor of the cell line ciPTEC-OAT1, for which the patent is held by Radboud University Nijmegen, the Netherlands. Timothy O’Brien, co-author of this manuscript and Editor-in-Chief of Stem Cell Research and Therapy, declares that he was not involved in the peer review or decision making of this article.